| 摘要 |
A method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, in humans or non-huma n mammals, which method comprises the administration of an effective, non-toxi c and pharmaceutically acceptable amount of PPARy agonist, such as Compound (I ), or a pharmaceutically acceptable derivative thereof. Conditions associated with cardiac insulin resistance are: microvascular angina, atherosclerosis a nd congestive heart failure. Compounds include rosiglitazone, troglitazone, englitazone and pioglitazone.
|
